Low versus high initial oral glucocorticoid dose for lupus nephritis: a pooled analysis of randomised controlled clinical trials (6 January, 2025) ...

T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for ...

Objectives SLE is a multifaceted autoimmune disorder with a complex pathogenesis involving genetic, environmental and ...

Objective Evaluating the potential role of neuromuscular ultrasonography (NMUS) in assessing optic nerve affection in ...

Objective Juvenile SLE (jSLE) is an autoimmune disease characterised by the presence of high levels of autoantibodies, predominantly targeting nuclear antigens, resulting in a breakdown of ...

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been approved as add-on therapies for SLE in China. The aim of this study is to ...

Introduction SLE is a chronic autoimmune disease that results in sustained hyperactivation of innate and adaptive immune cells and widespread inflammatory damage. Regular exercise reduces SLE symptoms ...

Objective Traditional initial treatment regimens for lupus nephritis (LN) used oral glucocorticoids (GC) in starting doses up to 1.0 mg/kg/day prednisone equivalent with or without a preceding ...